The CDKL1 antibody is a crucial tool in studying the function of Cyclin-Dependent Kinase-Like 1 (CDKL1), a serine/threonine kinase belonging to the CDK family. CDKL1 shares structural homology with other CDK-related proteins but exhibits distinct regulatory roles, primarily implicated in cell cycle progression, signal transduction, and cellular differentiation. Although less characterized than its paralog CDKL5 (linked to neurodevelopmental disorders), CDKL1 is thought to influence cell proliferation and tissue development through phosphorylation-mediated pathways. Its expression has been observed in various tissues, including the brain, testis, and certain cancers, suggesting potential roles in oncogenesis or tissue homeostasis.
CDKL1 antibodies are widely used in research to detect and quantify CDKL1 protein levels via techniques like Western blotting, immunohistochemistry (IHC), and immunofluorescence (IF). These antibodies aid in elucidating CDKL1's subcellular localization, interaction partners, and expression patterns under physiological or pathological conditions. For instance, studies have explored CDKL1's overexpression in cancers such as hepatocellular carcinoma, where it may promote tumor growth. Validated antibodies often undergo specificity checks using knockout controls or siRNA-mediated knockdown to ensure accurate detection.
Despite its emerging significance, CDKL1's precise mechanisms remain under investigation. The antibody thus serves as a vital reagent for uncovering its biological and clinical relevance, particularly in cancer research and developmental biology.